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Abstract 
Background 
The common symptoms of multiple sclerosis are fatigue, depression, cognitive dysfunction, pain 
and sexual dysfunction, which influence the health-related quality of life of the patients. 
Objective:  
We aimed to determine the correlations between the health-related quality of life, the level of 
disability, fatigue and depression in glatiramer acetate-treated patients with multiple sclerosis in 
Hungary.  
Methods:  
The Hungarian versions of the Multiple Sclerosis Quality of Life-54, Fatigue Impact Scale and 
Beck Depression Inventory questionnaires were completed by 428 relapsing-remitting multiple 
sclerosis patients treated with glatiramer acetate from 19 Hungarian centers.  
Results:  
The prevalence of fatigue was found to be 62.4%. The prevalence of depression was lower (13.4%) 
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than that described in previous studies (36-54%) among patients with multiple sclerosis. Significant 
differences in the health-related quality of life were found between fatigued and non-fatigued 
patients. The level of disability, fatigue, depression and the duration of the disease correlated 
significantly with the quality of life. However, linear regression analysis indicated that the quality 
of life was predicted by the level of disability, depression, social and cognitive fatigue, but not by 
physical fatigue.  
Conclusions:  
Decreasing the disease activity in multiple sclerosis with immunomodulatory therapy, together with 
improvements of the diagnostics and treatment of the accompanying depression and fatigue are of 
high priority to improve the health-related quality of life of patients with multiple sclerosis. 
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1.  Introduction 
Multiple sclerosis (MS) is a chronic disease, which, via its various symptoms, impairs the patients’ 
ability to move and work, as well as their level of well-being. Although the Expanded Disability 
Status Scale (EDSS) is generally used to determine the level of disability of patients with multiple 
sclerosis, several aspects of multiple sclerosis are not measurable with this scale (Kurtzke, 1983). In 
recent years, measurement of the health-related quality of life (HRQoL) became a useful tool to 
assess the burden of MS. HRQoL is a multidimensional parameter which relates to physical, mental 
and social health, and which is estimated by using general, combined and specific questionnaires 
(Hadgkiss et al., 2013). The common symptoms of multiple sclerosis are fatigue, depression, 
cognitive dysfunction, pain and sexual dysfunction, which synergistically influence the health-
related quality of life (Crayton et al., 2004). 
Fatigue is found in 40-90% of patients with multiple sclerosis (Lerdal et al., 2003), and 
fundamentally influences their daily routine. The patients’ capability of moving is better during the 
morning hours, but they need resting periods during longer activities. Fatigue also limits the 
patients’ personal interactions; moreover, it can even lead to losing their jobs. A patient with 
multiple sclerosis was reported, who presented fatigue as the only manifestation of an acute MS 
relapse (Flachenecker & Meissner, 2008). Futhermore, in another study, the correlation of fatigue 
and a cognitive sign of MS, alertness, was confirmed (Weinges-Evers et al., 2010). Three forms of 
fatigue have been described: physical, cognitive and social fatigue (Bakshi, 2003; Vucic et al., 
2010).  
The diagnosis and treatment of depression are essential in multiple sclerosis cases. Patten et al. 
concluded that major depression occurs in 15.7% of individuals with multiple sclerosis, which 
means a 2.3 times higher risk than in the normal population (Patten et al., 2003). A survey by 
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Ziemssen et al. suggested that major depression may occur in approximately 50% of patients with 
multiple sclerosis (Ziemssen, 2009). Only a small proportion of patients with multiple sclerosis 
receive effective treatment for their depression, and this situation, besides putting their 
uninterrupted 
 immunomodulatory therapy at risk, can lead to more severe fatigue, with a resulting negative 
influence on their health-related quality of life (Sadovnick et al., 1996). 
 Among the various modes of immunomodulatory therapy, the interferons can cause flu-like 
symptoms and fever, which can lead to secondary fatigue (Plosker, 2011). Sleep disorders can also 
cause secondary fatigue. Studies showed that sleep medical therapy may improve MS related 
fatigue (Veauthier et al., 2013; Veauthier & Paul, 2014). Furthermore, one of the adverse events of 
interferon beta treatment is depression. It was suggested that interferon beta induces secondary 
depression due to inhibition of serotonin production, however, long-term studies did not prove this 
hypothesis (Reder et al., 2014). For our study, we selected a group of glatiramer acetate-treated 
patients with multiple sclerosis, since the adverse events of glatiramer acetate (depression, flu-like 
symptoms, fever) are less common than those of interferon beta. 
 The aim of our study was to determine the prevalence of fatigue and depression in 
glatiramer acetate-treated patients with multiple sclerosis. Since we expected that fatigue negatively 
influences the health-related quality of life, we compared this parameter in fatigued and non-
fatigued patients. We analyzed the correlation of fatigue, depression, clinical disability and the 
disease duration with the health-related quality of life.  
2.  Methods 
2.1.   Participants 
 Data on 428 relapsing-remitting patients with multiple sclerosis treated with glatiramer 
acetate were collected from 19 Hungarian multiple sclerosis centers. The relevant socio-
demographic and disease-related data were obtained from the multiple sclerosis registers at the 
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centers. The diagnosis was confirmed according to the 2005 modification of the McDonald criteria 
for relapsing-remitting multiple sclerosis (McDonald et al., 2001; Polman et al., 2005). Patients 
were included in the study according to the following inclusion criteria: the patients had a relapsing-
remitting form of multiple sclerosis, glatiramer acetate treatment period was longer than one year, 
the patients were in remission for at least 30 days, the patients were off steroid therapy for more 
than 30 days, the patients had an EDSS score between zero and 5.5, and the patients were more than 
18 years old.  
 
2.2.  Ethics 
 The personal data on the patients were subject to strict confidentiality. All participants 
received appropriate information about the study both in written form and orally. They gave their 
written consent to statistical evaluation of their answers. The study was approved by the Science 
and Research-ethics Committee of the Medical Science Council in Hungary (3462-0/2010-
1018EKU (197/PI/10)) and was in full accord with the Declaration of Helsinki. The same, ethically 
approved information sheet and consent form were given to the participating patients at each center. 
 
2.3   Measures 
 The most frequently utilized questionnaire in multiple sclerosis to measure quality of life is 
the Multiple Sclerosis Quality of Life Questionnaire (MSQoL-54), which is a combined 
questionnaire, developed for English-speaking patients. It contains general questions regarding the 
quality of life (Short Form-36) and 18 specific questions for patients with multiple sclerosis 
(Vickrey et al., 1995). The MSQoL-54 enables the comparison of the quality of life of patients with 
multiple sclerosis with that of the general population and with that of patients with other diseases. 
The total of 54 questions can be divided into 14 groups: Physical health, Role limitations due to 
physical problems, Role limitations due to emotional problems, Pain, Emotional well-being, 
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Energy, Health perceptions, Social function, Cognitive function, Health distress, Overall quality of 
life, Sexual function, Satisfaction with sexual function and Change in health. The MSQoL-54 was 
validated for the Hungarian language (Füvesi et al., 2008), and the first survey with this 
questionnaire was performed in Hungary in 2010 (Füvesi et al., 2010). Apart from determining the 
health-related quality of life of multiple sclerosis patients, the survey demonstrated that 62% of the 
patients had at least one concomitant disease. Depression was found in 20.3% of the patients with 
multiple sclerosis.  
 The pathophysiology of fatigue is not well understood, and the objective characterization of 
fatigue is difficult. Recently, it was shown that fatigue is associated with the alterations of basal 
ganglia functional connectivity and with altered parameters of saccade like ocular motor 
movements, therefore testing these may lead to a better quantification of fatigue (Finke et al., 2012; 
Finke et al., 2015). However, questionnaires are widely used for this purpose. Although they are 
somewhat subjective, they yield useful information about the patients' everyday life. The most 
frequently used questionnaires are the Fatigue Severity Scale (FSS) (Krupp et al., 1989), the Fatigue 
Impact Scale (FIS) (Fisk et al., 1994), and the Modified Fatigue Impact Scale (MFIS) (Achiron et 
al., 2015). While the FSS is one-dimensional, measuring only physical fatigue, the FIS and MFIS 
assess all three aspects of fatigue. The completed FIS questionnaire contains 40 statements, the 
MFIS is a 21-item scale, each with a score ranging from 0 to 4 points, giving information on the last 
4 weeks. The Hungarian version of the FIS was validated in 2011 (Losonczi et al., 2011). 
 The Beck Depression Inventory - First Edition (BDI-I.) provides 21 grouped assertions on 
how the patient has been feeling in the last week. Each question has a set of at least four possible 
answers. With a total score above 21 points, the patient is regarded to have depression (Beck et al., 
1961). 
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2.4.   Statistical analysis  
 Statistical analysis was carried out with the Statistical Package for Social Sciences (SPSS 
19.0, SPSS Inc., http://www.spss.com); the level of significance was predefined at p < 0.05. For 
determination of the prevalence of fatigue and depression, we used frequency analysis. Correlation 
coefficients and partial correlation coefficients were applied to assess the influence of the EDSS 
score, depression, fatigue and the disease duration on the quality of life. The predictors of the 
quality of life were determined by linear regression. The data on the fatigued and the non-fatigued 
patients were compared with the independent samples t-test. Our study is an exploratory pilot study, 
so no correction for multiple comparisons was made. 
3.  Results 
3.1.   Demographic and clinical measures 
 The average age of the patients was 43.6 years (95% confidence interval [CI] 42.6–44.6), 
the male to female ratio was 1:2.8, the mean disease duration of multiple sclerosis from date of 
diagnosis was 11.2 years (95% CI 10.6–11.9), the mean duration of glatiramer acetate treatment was 
6.6 years (95% CI 6.2–6.9) and the median EDSS score was 2.0 (95% CI 2.2–2.5). The percentage 
of the married respondents was 60.7%, and 83.8% had one or two children. Around 66% had 
participated successfully in secondary education, and about 33% had done so in higher-level 
education. The distribution of patients among the multiple sclerosis centers is shown in Table I.  
3.2.   Main outcome measures 
 As concerns the responses to the MSQoL-54, FIS and BDI questionnaires by the 428 
glatiramer acetate-treated relapsing-remitting patients with multiple sclerosis in this multicentre 
study, 402 and 381 patients answered all questions in the FIS and BDI questionnaires, respectively. 
In each question group of the MSQoL-54, an average of 60 of the questionnaires could not be 
evaluated because of missing data. An exception was the question group relating to the sexual 
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function and the satisfaction with the sexual function, which were incomplete in more than 80 
cases.   
 The FIS scores indicated that the prevalence of fatigue was 62.4% (251 of 402 patients). The 
prevalence of depression was 13.4% (51 of 381 patients). Among the 278 patients who filled in both 
questionnaires completely, no one had depression without fatigue. However, 35 of the 168 fatigued 
patients also had depression (20.8%). Non-fatigued patients assessed their health-related quality of 
life significantly higher than patients with fatigue in all question groups of the MSQoL-54 
questionnaire (Table II).  
 By means of correlation analysis, we examined the correlation of the EDSS score, 
depression, the three dimensions of fatigue and the disease duration with the health-related quality 
of life, as examined with the MSQoL-54. Depression and the three dimensions of fatigue influenced 
all the subscales of the MSQoL-54 questions significantly negatively. The EDSS score correlated 
significantly negatively with all aspects of the MSQoL-54, except for the cognitive function scale. 
The disease duration had a significant negative correlation with the quality of life, with the 
exception of the mental health, the cognitive function and the satisfaction with the sexual function 
(Table III).  
 Regression analysis revealed that the overall quality of life was significantly predicted by 
the EDSS score, depression and social fatigue (Table IV). When the patients were grouped on the 
basis of the presence of depression, it emerged that in patients with depression, social fatigue was 
the only factor that predicted the quality of life (Table V). At question 54 of the MSQoL-54, the 
patients verbally evaluate their quality of life (terrible (1) - unhappy (2) - mostly grumbler (3) -
mixed (4) - mostly satisfied (5) - satisfied (6) - happy (7)). Regression analysis showed that the 
verbal characterization of the quality of life was predicted by the EDSS score, depression, social 
and cognitive fatigue (R2=0.389, p<0.05). As concerns the cognitive and the sexual quality of life, 
we found significant effects of depression and cognitive fatigue (Tables VI, VII). 
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4.  Discussion 
 The standardized prevalence of multiple sclerosis in Csongrád County, Hungary is 
83.7/100,000, 69% of the patients show the relapsing-remitting clinical form (Zsíros et al., 2014), 
and 78% of the relapsing-remitting patients is treated with immunomodulatory therapy. The 428 
patients examined in our study represent almost 10% of the Hungarian MS patients treated with 
immunomodulatory therapy, and more than 50% of the Hungarian MS patients treated with 
glatiramer acetate.    
 In this multicentre, cross-sectional study of Hungarian, relapsing-remitting multiple 
sclerosis patients treated with glatiramer acetate, we found a considerable prevalence of fatigue and 
depression. We also showed that these factors significantly contribute to the health-related quality 
of life of our patients. The 62.4% prevalence of fatigue after a mean disease duration of 11.23 years 
is in line with the literature data (Lerdal et al., 2003). Many international studies found that 
glatiramer acetate therapy may improve fatigue (Jongen et al., 2010; Jongen et al., 2014; Metz et al., 
2004; Ziemssen et al., 2008).  
 In previous studies, the prevalence of depression among patients with multiple sclerosis was 
found to be 36-54% (Ziemssen, 2009). Surprisingly, in our study, the prevalence was significantly 
lower (13.4%). The risk factors for depression in multiple sclerosis include the female gender, an 
age under 35 years, a family history of major depression and stress (Patten et al., 2000). Chwastiak 
et al. reported that depression correlated with a lower level of education, a younger age and the 
absence of social support, while a survey in Sarajevo, Bosnia and Herzegovina indicated that 
depression is more frequent among younger and middle-aged patients with a higher educational 
level and an unmarried status (Chwastiak et al., 2002; Alajbegovic et al., 2011). In the general 
population, depression is 1.7 to 2 times more frequent in females than in males (Kessler et al., 
1993), however, the above-mentioned studies did not detect this ratio in patients with MS.  
 The low prevalence of depression in our study may result from the interaction of a number 
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of factors. The majority of the respondent patients were married with one or two children. However, 
most of the patients (about 70%) declined to answer questions about their family status. The freely 
available phone service of multiple sclerosis nurses may also significantly influence the occurrence 
of depression among patients. This ensures stable and well-functioning medical support for patients 
with multiple sclerosis. The participants in this study had a relatively low median EDSS score, 
indicating a low level of physical disability. If introduced within a few years after the onset of 
multiple sclerosis, glatiramer acetate not only reduces the activity of the disease, but may also have 
an antidepressant effect (Tsai, 2007; Johnson, 2012).  
 Our correlation analysis also demonstrated that depression significantly influences the 
health-related quality of life. Depression has a strong influence on all aspects of the quality of life, 
and it can also mask the effects of fatigue, the EDSS score or the duration of the disease on quality 
of life.  
 Our results suggest that it is important to diagnose depression among multiple sclerosis 
patients, since depression can worsen their health-related quality of life, and its presence can 
influence the choice of immunomodulatory therapy. For patients with multiple sclerosis, who are 
susceptible to depression, glatiramer acetate is to be recommended since depression may occur as 
an adverse event of interferon beta therapy.  
 Depression in multiple sclerosis is often not well-diagnosed, and is not effectively treated 
(Marrie et al., 2009). The diagnosis is missed in around 23-30% of the cases, and around 20-36% of 
the patients are claimed to receive inadequate treatment of depression (McGuigan, & Hutchinson, 
2006). The effective treatment of depression is essential since, if left untreated, it may decrease the 
level of patient compliance, which may result in the cessation of immunomodulatory therapy.  
 According to several previous studies, fatigue can decrease the health-related quality of life 
significantly (Benedict et al., 2005; Janardhan & Bakshi, 2002; Lobentanz et al., 2004; Mitchell et 
al., 2005). In these studies, fatigue was examined as a one-dimensional factor. Our results are partly 
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contradictory to these findings, which may be explained by our different approach. We examined 
the three dimensions of fatigue separately, and found that physical fatigue does not predict the 
quality of life of multiple sclerosis patients. Social and cognitive fatigue, however, exerts 
significantly negative effects on the health-related quality of life. We cannot measure these with the 
EDSS, and it is not sure that the patients are willing to talk about their social difficulties or about 
their inability to lead a social life due to multiple sclerosis. We have to consider and strive to 
decrease the level of social fatigue, and thereby raise the patients’ quality of life perceptibly.  
 In the past decade, various surveys have emphasized the importance of depression and 
fatigue in multiple sclerosis, showing that these parameters, together with the EDSS score and the 
disease duration, significantly influence the health-related quality of life of patients with multiple 
sclerosis (Miller et al., 2003; Pittion-Vouyovitch et al., 2006). Recent studies in Iran and Poland on 
the influence of fatigue and depression on the health-related quality of life in multiple sclerosis 
yielded data that are in line with our results (Kargarfard et al., 2012; Papuc, & Stelmasiak, 2012).  
5.  Conclusions 
 Our study draws attention to the importance of estimation and follow-up of both social and 
cognitive fatigue and depression in multiple sclerosis. Besides the determination of the EDSS score, 
it is necessary to consider these symptoms as parameters, which influence the health-related quality 
of life. Their treatment adds further values to immunomodulatory therapy, and hence provides a 
better life for patients with multiple sclerosis.  
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Table I. Hungarian multiple sclerosis centers participating in the study 
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  Centers No. of 
patients 
1. Dept. of Neurol., F. Jahn Hosp. of South-Pest, Budapest, Hungary 48 
2. Dept. of Neurol., Hungarian Military Hosp., Budapest, Hungary 3 
3. Dept. of Neurol., St. István Hosp., Budapest, Hungary 4 
4. Dept. of Neurol., Univ. of Debrecen, Debrecen, Hungary 25 
5. Dept. of Neurol., Gy. Kenézy Hosp., Debrecen, Hungary 18 
6. Dept. of Neurol., A. Petz County Hosp., Győr, Hungary 11 
7. Dept. of Neurol., M. Kaposi Hosp., Kaposvár, Hungary 24 
8. Dept. of Neurol., Bács-Kiskun County Hosp., Kecskemét, Hungary 25 
9. Dept. of Neurol., BAZ County Hosp., Miskolc, Hungary 21 
10. Dept. of Neurol., A. Jósa Hosp., Nyíregyháza, Hungary 19 
11. Dept. of Neurol., Univ. of Pécs Med. School, Pécs, Hungary 40 
12. Dept. of Neurol., Univ. of Szeged, Szeged, Hungary 74 
13. Dept. of Neurol., Tolna County Hosp., Szekszárd, Hungary 9 
14. Dept. of Neurol., St. György Hosp., Székesfehérvár, Hungary 16 
15. Dept. of Neurol., G. Hetényi County Hosp., Szolnok, Hungary 18 
16. Dept. of Neurol., L. Markusovszky Hosp., Szombathely, Hungary 22 
17. Dept. of Neurol., K. Vaszary Hosp., Esztergom, Hungary 6 
18. Dept. of Neurol., Uzsoki St. Hosp., Budapest, Hungary 38 
19. Dept. of Neurol., Zs. Bajcsy Hosp., Budapest, Hungary 7 
 
Table II. Health-related quality of life of patients with or without fatigue   
 
  N Mean Std. 
deviatio
n 
Std. 
erro
r 
mea
n 
t-test for equality of meanst-test for equality of means 
 
t df Sig. 
(2-
taile
d) 
Mean 
differen
ce 
Std. 
error 
differen
ce 
95% CI of the 
diff. 
   Lower Upper 
"Overall
, how 
would 
you 
rate 
your 
own 
no 
fatigu
e 
13
1 
7.69 1.608 0.14 12.38
6 
323 0.00
1 
2.326 0.188 1.957 2.696 
fatigu
e 
19
4 
5.36 1.695 0.12
2 
12.51
4 
288.79
7 
0.00
1 
2.326 0.186 1.96 2.692 
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quality 
of life?" 
"Which 
best 
describ
es how 
you feel 
about 
your life 
as a 
whole?" 
no 
fatigu
e 
13
1 
5.39 1.113 0.09
7 
10.51
3 
325 0.00
1 
1.379 0.131 1.121 1.637 
fatigu
e 
19
6 
4.01 1.194 0.08
5 
10.66
1 
291.74
2 
0.00
1 
1.379 0.129 1.124 1.634 
Overall 
quality 
of life 
scale % 
no 
fatigu
e 
13
1 
75.01
3 
14.852 1.29
8 
13.14
4 
325 0.00
1 
23.014 1.751 19.57 26.45
9 
fatigu
e 
19
6 
51.99
8 
15.943 1.13
9 
13.33
1 
291.92 0.00
1 
23.014 1.727 19.61
7 
26.41
2 
General 
health 
scale % 
no 
fatigu
e 
13
1 
65.47
3 
20.318 1.77
5 
15.13
2 
325 0.00
1 
31.441 2.078 27.35
3 
35.52
8 
fatigu
e 
19
6 
34.03
2 
17.021 1.21
6 
14.61
3 
244.67
4 
0.00
1 
31.441 2.152 27.20
3 
35.67
9 
Cognitiv
e 
functio
n scale 
% 
no 
fatigu
e 
13
0 
85.69
2 
17.239 1.51
2 
11.42
3 
323 0.00
1 
26.923 2.357 22.28
6 
31.56 
fatigu
e 
19
5 
58.76
9 
22.888 1.63
9 
12.07
4 
318.16
7 
0.00
1 
26.923 23.02 22.53
6 
31.31 
Sexual 
functio
n scale 
% 
no 
fatigu
e 
12
8 
88.99
7 
16.367 1.44
7 
8.192 311 0.00
1 
24.973 3.049 18.97
5 
30.97
2 
fatigu
e 
18
5 
64.02
4 
31.68 2.32
9 
9.108 290.67
1 
0.00
1 
24.973 2.742 19.57
7 
30.37 
Bodily 
pain 
scale % 
no 
fatigu
e 
13
1 
82.92
4 
21.171 1.85 12.93
8 
323 0.00
1 
32.913 2.544 27.90
8 
37.91
8 
fatigu
e 
19
4 
50.01 23.347 1.67
6 
13.18
5 
296.50
3 
0.00
1 
32.913 2.496 28.00
1 
37.82
6 
 
Table III. Correlation of the level of disability, fatigue, depression and the duration of MS with the HRQoL 
 22 
 
  
  EDSS 
Cognitive 
fatigue 
Physical 
fatigue 
Social 
fatigue 
BDI 
Duration 
of disease 
Physical Functioning Scale r -0.541 -0.455 -0.707 -0.651 -0.423 -0.201 
p  0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 
Role-Physical Scale r -0.422 -0.516 -0.655 -0.66 -0.452 -0.209 
p  0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 
Role-Emotional Scale r -0.241 -0.581 -0.578 -0.643 -0.523 -0.153 
p  0.0001 0.0001 0.0001 0.0001 0.0001 0.003 
Bodily Pain Scale r -0.315 -0.567 -0.66 -0.655 -0.478 -0.138 
p  0.0001 0.0001 0.0001 0.0001 0.0001 0.008 
Pain Scale (Vickrey) r -0.304 -0.581 -0.666 -0.674 -0.526 -0.145 
p  0.0001 0.0001 0.0001 0.0001 0.0001 0.005 
Mental Health Scale r -0.181 -0.556 -0.569 -0.649 -0.716 -0.047 
p  0.0001 0.0001 0.0001 0.0001 0.0001 0.367 
Vitality Scale r -0.328 -0.578 -0.723 -0.721 -0.591 -0.125* 
p  0.0001 0.0001 0.0001 0.0001 0.0001 0.016 
Energy Scale (Vickrey) r -0.294 -0.577 -0.695 -0.705 -0.591 -0.134 
p  0.0001 0.0001 0.0001 0.0001 0.0001 0.01 
General Health Scale r -0.358 -0.59 -0.698 -0.712 -0.563 -0.135 
p  0.0001 0.0001 0.0001 0.0001 0.0001 0.009 
Social Functioning Scale r -0.272 -0.57 -0.643 -0.705 -0.58 -0.11* 
p  0.0001 0.0001 0.0001 0.0001 0.0001 0.033 
Social Function Scale (Vickrey) r -0.352 -0.605 -0.685 -0.739 -0.588 -0.151 
p  0.0001 0.0001 0.0001 0.0001 0.0001 0.003 
Cognitive Function Scale r -0.084 -0.764 -0.528 -0.648 -0.603 -0.057* 
p  0.106 0.0001 0.0001 0.0001 0.0001 0.276 
Health Distress Scale r -0.292 -0.56 -0.649 -0.701 -0.617 -0.1* 
p  0.0001 0.0001 0.0001 0.0001 0.0001 0.053 
Overall Quality of Life Scale r -0.369 -0.545 -0.617 -0.675 -0.674 -0.133 
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p  0.0001 0.0001 0.0001 0.0001 0.0001 0.01 
Sexual Function Scale r -0.224 -0.442 -0.517 -0.549 -0.486 -0.122* 
p  0.0001 0.0001 0.0001 0.0001 0.0001 0.022 
Reported Health Transition Scale r -0.262 -0.273 -0.412 -0.387 -0.317 -0.143 
 
p  0.0001 0.0001 0.0001 0.0001 0.0001 0.006 
Satisfaction with Sexual Function Scale r -0.211 -0.406 -0.426 -0.471 -0.525 -0.097* 
p  0.0001 0.0001 0.0001 0.0001 0.0001 0.071 
 
Correlation is significant at the 0.01 level (2-tailed). 
*Correlation is significant at the 0.05 level (2-tailed). 
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Table IV. Predictors of the overall quality of life scale by linear regression 
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Coefficients
a 
 Unstandardized coefficients 
Standardized 
coefficients 
 
B Std. error Beta t Sig. 
 (Constant) 18.184 0.306   59.46 0.0001 
EDSS -0.394 0.108 -0.155 -3.654 0.0001 
Cognitive fatigue 0.057 0.029 0.152 1.947 0.052 
Physical fatigue 0.032 0.033 0.094 0.996 0.320 
Social fatigue -0.148 0.023 -0.785 -6.329 0.0001 
Depression -1.742 0.478 -0.152 -3.643 0.0001 
a Dependent variable: overall quality of life scale (N=349, R2=0.519) 
 
Table V. Predictors of the overall quality of life scale among patients without or with depression by 
linear regression 
Coefficients
a 
    Unstandardized 
coefficients 
Standardized 
coefficients   
B Std. error Beta t Sig. 
No depression (Constant) 18.287 0.312   58.698 0.0001 
EDSS -0.436 0.114 -0.186 -3.843 0.0001 
Cognitive fatigue 0.058 0.031 0.157 1.875 0.062 
Physical fatigue 0.023 0.034 0.069 0.661 0.509 
Social fatigue -0.143 0.025 -0.768 -5.780 0.0001 
Depression (Constant) 
14.996 2.238 
 
6.702 0.0001 
EDSS -0.102 0.384 -0.046 -0.264 0.793 
Cognitive fatigue 0.05 0.094 0.133 0.529 0.600 
Physical fatigue 0.115 0.116 0.275 0.998 0.325 
Social fatigue -0.177 0.081 -0.707 -2.200 0.034 
a
 Dependent variable: overall quality of life scale  (N=305 and 44, R
2
=0.448 and 0.170, respectively) 
 
 
Table VI. Predictors of the cognitive quality of life by linear regression 
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Coefficients
a  
 Unstandardized coefficients Standardized 
coefficients 
  
B Std. error Beta t Sig.  
 (Constant) 85.468 2.060   41.499 0.0001  
Depression 
-10.716 3.389 -0.142 -3.162 0.002  
EDSS 
1.344 0.744 0.082 1.806 0.072  
Cognitive fatigue 
-27.332 2.988 -0.55 -9.147 0.0001  
Physical fatigue 
-2.642 3.693 -0.051 -0.715 0.475  
Social fatigue 
-6.473 3.891 -0.13 -1.663 0.097  
a
 Dependent variable: cognitive function scale % (N=276, R
2
=0.527) 
 
Table VII. Predictors of the sexual quality of life by linear regression 
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Coefficients
a  
  
Unstandardized coefficients 
Standardized 
coefficients 
  
B Std. error Beta t Sig.  
(Constant) 
91.62 3.077   29.774 0.0001  
Depression 
-16.605 
5.130 -0.182 -3.237 0.001  
EDSS 
-1.705 1.121 -0.086 -1.521 0.129  
Cognitive fatigue 
-14.892 4.468 -0.249 -3.333 0.001  
Physical fatigue 
0.511 5.503 0.008 0.093 0.926  
Social fatigue 
-11.049 5.799 -0.185 -1.905 0.058  
a
 Dependent variable: sexual function scale % (N=271, R
2
=0.273 ) 
 
Highlights: 
 The prevalence of fatigue and depression was found to be 62.4% and 13.4%, respectively. 
 Significant differences in the quality of life were found between fatigued and non-fatigued 
patients. 
 The quality of life was predicted by EDSS, depression, social and cognitive fatigue. 
 
 
